Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Zepbound, which is FDA-approved for chronic weight management. At PEAK, we prescribe Zepbound for weight-loss patients.
How Mounjaro Dosing Works
Mounjaro (tirzepatide) uses a 6-step graduated dosing approach. Unlike some medications where the starting dose is also the maintenance dose, tirzepatide begins at a sub-therapeutic level and escalates over months to reach the dose that provides optimal results for each patient.
The 6-dose range (2.5 mg through 15 mg) provides more granularity than many GLP-1 medications, allowing providers to fine-tune treatment. Not every patient needs to reach the maximum dose—some achieve excellent results at intermediate levels.
Same molecule, same doses: Mounjaro (for diabetes) and Zepbound (for weight management) use identical tirzepatide at the same dose levels. The titration schedule is the same regardless of indication.
The Standard Titration Schedule
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Initiation | 2.5 mg | Weeks 1–4 | GI adaptation; not a therapeutic dose |
| Early Therapeutic | 5 mg | Weeks 5–8 | First therapeutic dose; meaningful effect begins |
| Mid Titration | 7.5 mg | Weeks 9–12 | Intermediate dose; significant appetite/weight effects |
| High Therapeutic | 10 mg | Weeks 13–16 | Strong efficacy; many patients maintain here |
| Upper Titration | 12.5 mg | Weeks 17–20 | Near-maximum dose; further weight loss |
| Maximum | 15 mg | Week 21+ | Maximum available dose; greatest weight loss |
Each dose is held for a minimum of 4 weeks before the next increase. Your provider may recommend staying at any dose longer if:
- You’re experiencing significant GI side effects at the current dose
- Results are satisfactory without further escalation
- You prefer a more conservative titration pace
There is no clinical requirement to reach 15 mg. The SURMOUNT trials (which studied tirzepatide as Zepbound for weight management) showed clinically meaningful results at every dose level.
Mounjaro vs. Zepbound: Dosing Comparison
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Available doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Starting dose | 2.5 mg weekly | 2.5 mg weekly |
| Maximum dose | 15 mg weekly | 15 mg weekly |
| Injection frequency | Once weekly | Once weekly |
The products are pharmacologically identical. The only differences are the brand name, packaging, and FDA-approved indication—which affects insurance coverage pathways.
Missed Dose Guidance
Tirzepatide has a half-life of approximately 5 days, providing some flexibility:
- Within 4 days of scheduled dose: Take the injection as soon as you remember, then resume your regular schedule
- More than 4 days late: Skip the missed dose and take the next one on your regular day
- Two or more consecutive missed doses: Contact your provider. You may need to restart at a lower dose
Consistency matters more than perfection. One missed dose rarely impacts long-term results. Regular missed doses, however, reduce effectiveness and can cause more side effects when restarting.
Injection Details
Mounjaro uses a single-dose, pre-filled auto-injector pen. Unlike some other GLP-1 pens, each Mounjaro pen contains exactly one dose.
Injection Sites
- Abdomen: At least 2 inches from belly button
- Thigh: Front or outer upper thigh
- Upper arm: Back of the arm (may need assistance)
Practical Tips
- Rotate injection sites weekly
- Store unused pens in the refrigerator (36°F–46°F)
- An unused pen can be stored at room temperature (up to 86°F) for up to 21 days
- Choose a consistent injection day; many patients prefer Friday evening or Saturday morning
What Results to Expect at Each Dose
Based on SURMOUNT trial data (tirzepatide studied as Zepbound for weight management):
| Dose | Average Weight Loss | Notable |
|---|---|---|
| 2.5 mg | Minimal (adaptation) | GI adjustment phase; appetite changes begin |
| 5 mg | ~16% (at 72 weeks) | Clinically meaningful even without escalation |
| 10 mg | ~21% (at 72 weeks) | Strong results; common maintenance dose |
| 15 mg | ~22.5% (at 72 weeks) | Maximum efficacy; incremental gain over 10 mg |
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
